Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic HIV Immunisations with or without IL-2, GM-CSF and Growth Hormone in HAART-treated HIV-1 Patients
2006-006212-30Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of somatropin, IR103, aldesleukin and sargramostim in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Imperial College London. Primary endpoint: Primary cellular immune response. Started Jun 2007; status: completed.
02
Drugs
somatropinIR103aldesleukinsargramostim
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-006212-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006212-30.